AI automatic translation Rosetta webinar “Measures for FDA remote monitoring tool renewal-preparing for remote regulatory assessment-” held on November 24 (Thursday)
Rosetta Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, CEO: Maro Watanabe), which develops and operates high-precision AI automatic translation, has released a free webinar “Measures for FDA remote monitoring tool renewal-preparing for remote regulatory assessment-“. It will be held on Thursday, November 24, 2022.
【How to apply】
Please register from the participation application form in the middle of the page.
*After registration is completed, we will send you an email with the participation URL.
Did you know that the draft guidance was published on July 22, 2022 and the FDA’s remote monitoring tool site was updated on July 25, 2022?
In this webinar, we will introduce how to develop an environment in-house that can efficiently translate FDA guidance, etc., with explanations of our AI translation “T-4OO”.
How should I prepare the materials to be presented to the inspector in advance? We will take up specific business cases and issues and tell you how to prepare for FDA inspections with practical content. [Recommended for people like this]
・Those whose work is under pressure due to an increase in inspections due to the calmness of the corona crisis
・Those who want to automate non-core work such as translation work and concentrate on core work
・Those who want to further improve productivity by capitalizing past translation memories
・ Those who are looking for a way to communicate properly with inspectors ・Those who want to know what is standardized terminology/parallel translation registration in translation tools
・Those who work in the pharmaceutical/medical device/chemical industry and want to update their knowledge of FDA guidelines in a timely manner
[Date and time]
November 24, 2022 (Thursday) 14:00-14:40
Held on Zoom.
For those who have applied for participation, we will send you a zoom url by email the day before the event.
・Even if there are multiple participants, please apply for
participation one by one.
・Participation by other companies in the same industry or individuals may be refused.
Details about this release: